MCID: TCL024
MIFTS: 27

T-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for T-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for T-Cell Non-Hodgkin Lymphoma:

Name: T-Cell Non-Hodgkin Lymphoma 58
T-Cell Nhl 58

Characteristics:


Prevelance:

1-9/1000000 (Europe) 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

UMLS via Orphanet 72 C0079772
Orphanet 58 ORPHA171918

Summaries for T-Cell Non-Hodgkin Lymphoma

MalaCards based summary: T-Cell Non-Hodgkin Lymphoma, also known as t-cell nhl, is related to angioimmunoblastic t-cell lymphoma and t-cell lymphoma, subcutaneous panniculitis-like. An important gene associated with T-Cell Non-Hodgkin Lymphoma is HAVCR2 (Hepatitis A Virus Cellular Receptor 2). The drugs Ifosfamide and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and liver.

Related Diseases for T-Cell Non-Hodgkin Lymphoma

Diseases in the B-Cell Non-Hodgkin Lymphoma family:

T-Cell Non-Hodgkin Lymphoma

Diseases related to T-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 angioimmunoblastic t-cell lymphoma 11.6
2 t-cell lymphoma, subcutaneous panniculitis-like 11.5
3 enteropathy-associated t-cell lymphoma 11.5
4 primary cutaneous t-cell non-hodgkin lymphoma 11.5
5 anaplastic large cell lymphoma 11.4
6 alk-positive anaplastic large cell lymphoma 11.4
7 alk-negative anaplastic large cell lymphoma 11.4
8 hepatosplenic t-cell lymphoma 11.4
9 primary cutaneous gamma-delta t-cell lymphoma 11.4
10 primary lymphoma of the conjunctiva 11.4
11 primary cutaneous anaplastic large cell lymphoma 11.4
12 lymphoma, hodgkin, classic 11.0
13 lymphoma, non-hodgkin, familial 11.0
14 lymphoma 11.0
15 burkitt lymphoma 10.7
16 peripheral t-cell lymphoma 10.5
17 fungal infectious disease 10.5
18 mycosis fungoides 10.5
19 b-cell lymphoma 10.4
20 thrombophilia due to thrombin defect 10.3
21 leukemia, acute lymphoblastic 10.3
22 diffuse large b-cell lymphoma 10.3
23 nasal type extranodal nk/t-cell lymphoma 10.3
24 neutropenia 10.3
25 leukemia, chronic lymphocytic 10.2
26 factor vii deficiency 10.2
27 mature t-cell and nk-cell lymphoma 10.2
28 thrombocytopenia 10.2
29 viral infectious disease 10.2
30 b-cell non-hodgkin lymphoma 10.2
31 autoimmune disease 10.1
32 breast cancer 10.1
33 kaposi sarcoma 10.1
34 li-fraumeni syndrome 10.1
35 lipomatosis, multiple 10.1
36 sarcoidosis 1 10.1
37 ascites, chylous 10.1
38 lung cancer 10.1
39 fanconi anemia, complementation group a 10.1
40 immune deficiency disease 10.1
41 hemophagocytic lymphohistiocytosis, familial, 1 10.1
42 loose anagen hair syndrome 10.1
43 leukemia, acute myeloid 10.1
44 human immunodeficiency virus type 1 10.1
45 sarcoidosis 2 10.1
46 myelodysplastic syndrome 10.1
47 graft-versus-host disease 10.1
48 deficiency anemia 10.1
49 exanthem 10.1
50 ptosis 10.1

Graphical network of the top 20 diseases related to T-Cell Non-Hodgkin Lymphoma:



Diseases related to T-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for T-Cell Non-Hodgkin Lymphoma

Drugs & Therapeutics for T-Cell Non-Hodgkin Lymphoma

Drugs for T-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 4 3778-73-2 3690
2
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
3
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
4
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
5
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
6
Palifosfamide Investigational Phase 4 31645-39-3 100427
7
Pirarubicin Investigational Phase 4 72496-41-4 4844
8 Antibiotics, Antitubercular Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antimetabolites Phase 4
11 Folic Acid Antagonists Phase 4
12 Folate Phase 4
13 Vitamin B9 Phase 4
14 Vitamin B Complex Phase 4
15 Liposomal doxorubicin Phase 4
16
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
17
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
18
Etoposide Approved Phase 2 33419-42-0 36462
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
21
Picropodophyllin Approved, Investigational Phase 1, Phase 2 518-28-5, 477-47-4 10607 72435
22
Ondansetron Approved Phase 2 99614-02-5 4595
23
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
24
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
25
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
26
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
27
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
28
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
29
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
31
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
32
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
33
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
34
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
35
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
36
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
37
Nivolumab Approved Phase 2 946414-94-4
38
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
39
Mogamulizumab Approved, Investigational Phase 1, Phase 2 1159266-37-1
40
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
41
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704
42
Acetic acid Approved Phase 2 64-19-7 176
43
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
44
Letermovir Approved, Investigational Phase 2 917389-32-3 9916099 45138674
45
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
46
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
47
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
48
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
49
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
50
Lenalidomide Approved Phase 2 191732-72-6 216326

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
3 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT04021082 Phase 2, Phase 3 Cerdulatinib
4 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
5 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
6 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
7 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
8 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
9 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
10 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
11 Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC) Completed NCT00723099 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
12 A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies Completed NCT01921387 Phase 1, Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan
13 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
14 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
15 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
16 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
17 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
18 A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma Completed NCT00684411 Phase 2 Imatinib mesylate
19 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
20 Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas Completed NCT01076543 Phase 1, Phase 2 Lenalidomide;Temsirolimus
21 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
22 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
23 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
24 A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease Completed NCT00003210 Phase 2
25 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
26 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
27 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
28 Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen Completed NCT00992446 Phase 2 Bortezomib;Carmustine;Cytarabine;Etoposide;Melphalan;Rituximab;Vorinostat
29 A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma Completed NCT00961220 Phase 1, Phase 2 Carmustine;O6-Benzylguanine
30 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
31 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
32 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
33 Post Transplant Infusion of Allogeneic CD8 Memory T-Cells as Consolidative Therapy After Non-myeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Leukemia and Lymphoma Completed NCT02424968 Phase 2 Cyclosporine;Mycophenolate Mofetil
34 A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01431209 Phase 2 Ruxolitinib Phosphate
35 A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL) Completed NCT01994382 Phase 1, Phase 2 Cerdulatinib
36 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
37 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
38 A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas Recruiting NCT03409432 Phase 2 Brentuximab Vedotin;Lenalidomide
39 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
40 A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Recruiting NCT03278782 Phase 1, Phase 2 Romidepsin
41 A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma Recruiting NCT03011814 Phase 1, Phase 2 Lenalidomide
42 Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Recruiting NCT03210662 Phase 2
43 A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma Recruiting NCT03590574 Phase 1, Phase 2
44 Mogamulizumab and Extracorporeal Photopheresis (ECP) for the Treatment of Sézary Syndrome and Erythrodermic Mycosis Fungoides, a Phase 1b/2 Study Recruiting NCT04676087 Phase 1, Phase 2
45 A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL Recruiting NCT04930653 Phase 2
46 Letermovir for Cytomegalovirus Prophylaxis in Patients With Hematological Malignancies Treated With Alemtuzumab Recruiting NCT04312841 Phase 2 Letermovir
47 Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas Recruiting NCT05053971 Phase 1, Phase 2 BET Bromodomain Inhibitor ZEN-3694;Entinostat
48 Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas Recruiting NCT02859402 Phase 2 Busulfan;Fludarabine
49 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
50 Pilot Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Recruiting NCT04217317 Phase 2 CPI 613;Bendamustine

Search NIH Clinical Center for T-Cell Non-Hodgkin Lymphoma

Genetic Tests for T-Cell Non-Hodgkin Lymphoma

Anatomical Context for T-Cell Non-Hodgkin Lymphoma

Organs/tissues related to T-Cell Non-Hodgkin Lymphoma:

MalaCards : T Cells, Bone Marrow, Liver, Nk Cells, Bone, Myeloid, Skin

Publications for T-Cell Non-Hodgkin Lymphoma

Articles related to T-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 415)
# Title Authors PMID Year
1
Inter-intra instrument comparison and standardization of a 10-color immunophenotyping for B and T cell non-Hodgkin lymphoma diagnosis and monitoring. 62
36243108 2022
2
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma. 62
36260690 2022
3
Clinicopathological Spectrum of Hodgkin's and Non-Hodgkin's Lymphoma: A Tertiary Care Cancer Hospital Study in Pakistan. 62
35784957 2022
4
Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma. 62
34506624 2022
5
Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report. 62
35006005 2022
6
Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation. 62
35537403 2022
7
Two young patients with extranodal natural killer/T-cell non-Hodgkin lymphoma, nasal-type (ENKTL-NT) masquerading inflammatory processes: A case series. 62
35813787 2022
8
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. 62
35106754 2022
9
Prognostic evaluation models for primary thyroid lymphoma, based on the SEER database and an external validation cohort. 62
34865184 2022
10
Epstein-Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. 62
34626122 2022
11
Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma. 62
35239073 2022
12
An Updated Approach and Understanding of Breast Implant-Associated Anaplastic Large Cell Lymphoma. 62
35276670 2022
13
[Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma]. 62
35123616 2022
14
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): a good practice guide, pictorial review, and new perspectives. 62
34579859 2022
15
Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas. 62
35267494 2022
16
BIA-ALCL diagnosis on CytoLyt fixed ThinPrep, cell block and immunohistochemistry. 62
34623773 2022
17
Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with Indolent Behavior. 62
35070213 2022
18
T-Cell Non-Hodgkin Lymphoma of the Ileum Presenting as Perforation and Peritonitis: A Case Report. 62
35372472 2022
19
Immunotherapy in indolent Non-Hodgkin's Lymphoma. 62
35663281 2022
20
Mode of Delivery, Birth Characteristics, and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study. 62
34548330 2021
21
Ukrainian prospective study in patients with T-cell non-Hodgkin lymphomas. 62
34967534 2021
22
Occupational insecticide exposure and risk of non-Hodgkin lymphoma: A pooled case-control study from the InterLymph Consortium. 62
34270795 2021
23
Metagenomic analysis to identify novel infectious agents in systemic anaplastic large cell lymphoma. 62
34775986 2021
24
Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study. 62
34124779 2021
25
Primary gastrointestinal anaplastic large cell lymphoma: A critical reappraisal with a systematic review of the world literature. 62
34916358 2021
26
MRI features of breast implant-associated anaplastic large cell lymphoma. 62
33989039 2021
27
Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. 62
34860565 2021
28
FANCA, TP53, and del(5q)/RPS14 alterations in a patient with T-cell non-Hodgkin lymphoma and concomitant Fanconi anemia and Li-Fraumeni syndrome. 62
33183999 2021
29
Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). 62
33461261 2021
30
The management of breast implant-associated anaplastic large cell lymphoma in the setting of pregnancy: seeking for clinical practice guidelines. 62
34352947 2021
31
Primary soft tissue sarcoma: stage IV extranodal T-cell non-Hodgkin's lymphoma. 62
34326112 2021
32
The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma. 62
33211280 2021
33
Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis. 62
33629825 2021
34
Epstein-Barr virus positive diffuse large B-cell lymphoma transformed into angioimmunoblastic T-cell lymphoma after treatment. 62
34084501 2021
35
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. 62
33512419 2021
36
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. 62
33451977 2021
37
Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. 62
32550718 2021
38
UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group. 62
33222158 2021
39
UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). 62
33358076 2021
40
NK/T-cell non-Hodgkin lymphoma: Case report and review of the literature. 62
33363602 2021
41
UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). 62
33483089 2021
42
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. 62
32980545 2021
43
Post-Chemotherapy Rebound Thymic Hyperplasia Mimicking Relapse in Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report. 62
33730738 2021
44
Experience with Orbital Tumors from a Tertiary Cancer Centre of North East India: A Pathology Perspective. 62
33268934 2020
45
Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma. 62
32916604 2020
46
Immunotherapy for T-Cell ALL and T-Cell NHL. 62
32862870 2020
47
A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin. 62
32884752 2020
48
Primary dural lymphomas: Clinical presentation, management, and outcome. 62
32176324 2020
49
Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16-/CD16 + monocyte ratio. 62
32385351 2020
50
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities. 62
31822802 2020

Variations for T-Cell Non-Hodgkin Lymphoma

Expression for T-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for T-Cell Non-Hodgkin Lymphoma.

Pathways for T-Cell Non-Hodgkin Lymphoma

GO Terms for T-Cell Non-Hodgkin Lymphoma

Sources for T-Cell Non-Hodgkin Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....